Fill out the form to download a preview of this report. The full report is available through the PitchBook Platform.
Mega-rounds slow in retail healthtech
Demand for mobile & digital healthtech skyrocketed during the pandemic. While interest is still high, it may not be rising as rapidly, as demand was pulled forward for at-home fitness equipment. Additionally, but gyms are reopening and in-person doctor visits are becoming safe again.
Our latest installment of Emerging Tech Research explores key trends, VC activity and new business opportunities in the retail healthtech sector.
Key takeaways
- Deal value in the space dropped to $2.6 billion in Q3 from $3.5 billion in Q2, while disclosed median deal size declined to $11 million, largely due to a decrease in mega-deals.
- VC exit value fell to $2.4 billion—following Q2’s record $7.6 billion, which included the public listing of 23andMe.
- Emerging opportunities in the industry include utilization-based insurance for high-cost digital therapeutics and startups developing applications to help patients utilize data from continuous glucose monitors.
Table of contents
| Vertical overview | 3 |
| Q3 2021 timeline | 4 |
| Retail healthtech VC ecosystem market map | 5 |
| VC activity | 6 |
| Emerging opportunities | 14 |
| Utilization-based reimbursement | 15 |
| Continuous glucose monitoring | 17 |
| Select company highlights | 20 |
| Gennev | 21 |
| Iron Ox | 23 |